Chester County News and Community Website
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it will expand development of its investigational therapy QTORIN™ 3.9% rapamycin anhydrous gel into clinically significant angiokeratomas, a rare and debilitating …
Palvella Expands QTORIN Rapamycin Program Into Rare Angiokeratomas Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it has completed TOIVA, a Phase 2 proof-of-concept trial of QTORIN™ 3.9% rapamycin anhydrous gel, for the treatment of cutaneous venous …
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Cutaneous Venous Malformations Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has completed TOIVA, its Phase 2 clinical trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel as a potential treatment for cutaneous venous malformations …
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Rare Skin Disorder Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has appointed David W. Osborne, Ph.D., as Chief Innovation Officer, bringing more than 25 years of experience in developing therapies for difficult-to-treat …
Palvella Therapeutics Names David W. Osborne, Ph.D. as Chief Innovation Officer Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced that Chief Executive Officer Wes Kaupinen will present at two major investor conferences in September.
Palvella Therapeutics to Present at Upcoming Healthcare Conferences Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced that Founder and CEO Wes Kaupinen will take part in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference. …
Palvella Therapeutics CEO to Speak at Canaccord Genuity Growth Conference Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced its inclusion in both the Russell 3000® Index and the Russell 2000® Index as part of the 2025 reconstitution of …
Palvella Therapeutics Joins Russell 3000 and Russell 2000 Indexes Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has successfully completed enrollment in the Phase 3 SELVA clinical trial of QTORIN™ 3.9% rapamycin anhydrous gel, a potential breakthrough treatment for …
Palvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN Rapamycin Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the issuance of U.S. patent No. 12,329,748 by the United States Patent and Trademark Office (USPTO), providing increased protection for its …
Palvella Therapeutics Secures New Patent for QTORIN™ Rapamycin Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has received the initial proceeds from a prestigious FDA Orphan Products Development grant to support its ongoing Phase 3 SELVA trial of …
Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin Read More